Source comparison
ARA-290 Dosage Neuroprotection: Protocol Comparison
Acute Neuroprotection (Post-Injury) 4–6mg subcutaneous 3× weekly 4–8 weeks Stroke, traumatic brain injury, acute nerve damage Supported by ARISE trial data; aims to reduce inflammatory cascade during critical repair window. Front-load dosing in first 2 weeks.
This comparison does not assign a generated winner or score.
- Acute Neuroprotection (Post-Injury)
- 4–6mg subcutaneous
- 3× weekly
- 4–8 weeks
- Stroke, traumatic brain injury, acute nerve damage
- Supported by ARISE trial data; aims to reduce inflammatory cascade during critical repair window. Front-load dosing in first 2 weeks.
- Chronic Maintenance (Neurodegenerative)
- 2–3mg subcutaneous
- 2× weekly
- 12–24 weeks
- Parkinson's, MS, diabetic neuropathy, chemotherapy-induced neuropathy
- Lower dose with longer duration targets sustained microglial modulation. Monitor symptom trajectory every 4 weeks. Lack of improvement by week 8 suggests poor IRR responsiveness.
- High-Dose Experimental (Gray Market)
- 8–12mg subcutaneous
- Daily or 5× weekly
- Variable
- Not evidence-based
- No published data support benefit above 8mg per dose. Increased injection site reactions, potential receptor desensitization, and unnecessary peptide waste. Avoid.
- Preventive/Cognitive Enhancement
- 1–2mg subcutaneous
- Open-ended
- Healthy individuals seeking neuroprotection
- Minimal human data in non-disease populations. IRR expression is lower in metabolically healthy tissue. Questionable whether benefit exists without baseline inflammation.